CV Therapeutics's Ranexa Reduces Chest Pain in Angina Patients
Posted on: Wednesday, 2 April 2008, 09:01 CDT
CV Therapeutics has reported that Ranexa significantly reduced the risk of recurrent ischemia, worsening angina and intensification of antianginal therapy, in angina patients in the Merlin-Timi 36 study.
Additionally, Ranexa has significantly improved all measures of exercise performance compared to placebo, including reductions in the time to onset of angina (p=0.002) and time to the onset of 1mm ST segment depression (p=0.002), a signal of ischemia, in these Merlin-Timi 36 angina patients.
David Morrow, lead investigator of the Merlin-Timi 36 study, said: "This new subgroup analysis shows consistent safety and efficacy across a broader group of angina patients than those studied previously and reaffirms ranolazine as an option for treating chronic angina."
Source: Datamonitor
Related Articles
- Heart Study Shows Many Suffer Poor Quality Of Life
- Certain Combined Medications Following Heart Attack Could Increase Risk Of Death
- Most Angina Patients Not Being Tested
- Pfizer's Lipitor Provides Potent Heart Benefit in Angina Patients
- Stem Cell Transplants Aid Angina Patients
- MultiVu Video Feed: New Hope for 9 Million Americans Suffering From Angina, Debilitating Cardiac Chest Pain
- Angina Patients Cost Managed Care Over Twice As Much As Coronary Artery Disease Patients Without Angina
- Beta-Blocker Therapy Could Be Risky for Some Heart Patients
- Angiogenix Announces Phase II Data for ACCLAIM
 |
 |
User Comments (0)
RSS Feeds